Reckitt Benckiser has today received regulatory approval for its acquisition of Mead Johnson.
The $16.7bn (£13.2m) acquisition is expected to take place on 15 June.
The deal was being examined by China’s ministry of commerce because Mead Johnson has a large exposure to Chinese markets.
The Durex owner announced its intention to take over US group Mead Johnson, a baby formula maker, in February.
The transaction is being financed through cash and debt. It is buying Mead Johnson’s shares at $90 each.
Reckitt Benckiser owns a portfolio of brands including Cillit Bang, Strepsils and Gaviscon, and the mega-merger will allow the firm to move into the higher-margin health food market.
Chief executive officer of Reckitt Benckiser, Rakesh Kapoor, said the deal was a “significant step forward” for the company.
Mead Johnson is also well-established in emerging markets across Asia, providing a growth opportunity for the merged group.